178 related articles for article (PubMed ID: 29674496)
21. Elucidation of Novel Therapeutic Targets for Acute Myeloid Leukemias with
Yun JW; Bae YK; Cho SY; Koo H; Kim HJ; Nam DH; Kim SH; Chun S; Joo KM; Park WY
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30959925
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.
Cho EK; Bang SM; Ahn JY; Yoo SM; Park PW; Seo YH; Shin DB; Lee JH
Korean J Intern Med; 2003 Mar; 18(1):13-20. PubMed ID: 12760263
[TBL] [Abstract][Full Text] [Related]
23. RNA interference and deep sequencing as tools for identifying new genes involved in leukemogenesis.
Lebedev TD; Spirin PV; Orlova NN; Kudryavtseva AV; Melnikova NV; Speranskaya AS; Prasolov VS
Dokl Biochem Biophys; 2013; 448():49-51. PubMed ID: 23478988
[No Abstract] [Full Text] [Related]
24. ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation.
Liu J; Lu W; Liu S; Wang Y; Li S; Xu Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Leuk Res; 2018 May; 68():15-21. PubMed ID: 29518627
[TBL] [Abstract][Full Text] [Related]
25. Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML.
Steinauer N; Guo C; Huang C; Wong M; Tu Y; Freter CE; Zhang J
Blood Adv; 2019 May; 3(9):1379-1393. PubMed ID: 31040112
[TBL] [Abstract][Full Text] [Related]
26. Spontaneous cell fusion of acute leukemia cells and macrophages observed in cells with leukemic potential.
Martin-Padura I; Marighetti P; Gregato G; Agliano A; Malazzi O; Mancuso P; Pruneri G; Viale A; Bertolini F
Neoplasia; 2012 Nov; 14(11):1057-66. PubMed ID: 23226099
[TBL] [Abstract][Full Text] [Related]
27. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.
Barseguian K; Lutterbach B; Hiebert SW; Nickerson J; Lian JB; Stein JL; van Wijnen AJ; Stein GS
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15434-9. PubMed ID: 12427969
[TBL] [Abstract][Full Text] [Related]
28. Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML.
Trinh BQ; Ummarino S; Zhang Y; Ebralidze AK; Bassal MA; Nguyen TM; Heller G; Coffey R; Tenen DE; van der Kouwe E; Fabiani E; Gurnari C; Wu CS; Angarica VE; Yang H; Chen S; Zhang H; Thurm AR; Marchi F; Levantini E; Staber PB; Zhang P; Voso MT; Pandolfi PP; Kobayashi SS; Chai L; Di Ruscio A; Tenen DG
Blood; 2021 Oct; 138(15):1331-1344. PubMed ID: 33971010
[TBL] [Abstract][Full Text] [Related]
29. NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells.
Hackanson B; Abdelkarim M; Jansen JH; Lübbert M
Leukemia; 2010 Apr; 24(4):860-1. PubMed ID: 20090777
[No Abstract] [Full Text] [Related]
30. Disruption of MAPK1 expression in the ERK signalling pathway and the RUNX1‑RUNX1T1 fusion gene attenuate the differentiation and proliferation and induces the growth arrest in t(8;21) leukaemia cells.
Bashanfer SAA; Saleem M; Heidenreich O; Moses EJ; Yusoff NM
Oncol Rep; 2019 Mar; 41(3):2027-2040. PubMed ID: 30569130
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
Kawashima N; Akashi A; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kitamura K; Sakaida E; Takeshita A; Suzushima H; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
Ann Hematol; 2019 Jan; 98(1):83-91. PubMed ID: 30251205
[TBL] [Abstract][Full Text] [Related]
32. The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor.
Wildonger J; Mann RS
Development; 2005 May; 132(10):2263-72. PubMed ID: 15829516
[TBL] [Abstract][Full Text] [Related]
33. Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21).
Kwong YL; Chan V; Wong KF; Chan TK
Cancer; 1995 Feb; 75(3):821-5. PubMed ID: 7828132
[TBL] [Abstract][Full Text] [Related]
34. Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia.
Cheng CK; Chan NP; Wan TS; Lam LY; Cheung CH; Wong TH; Ip RK; Wong RS; Ng MH
Haematologica; 2016 Apr; 101(4):448-57. PubMed ID: 26802049
[TBL] [Abstract][Full Text] [Related]
35. Relapsed RUNX1-RUNX1T1-positive acute myeloid leukemia with pseudo-Chediak-Higashi granules.
Kondo H; Kanayama T; Matsumura U; Urata T; Osone S; Imamura T; Inaba T; Hosoi H
Int J Hematol; 2021 May; 113(5):616-617. PubMed ID: 33782817
[No Abstract] [Full Text] [Related]
36. [Correlations Between
Wang XM; Ye YX; Yang L; Lu XJ; Ying BW
Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Nov; 47(6):931-935. PubMed ID: 28598127
[TBL] [Abstract][Full Text] [Related]
37. The molecular signature of oncofusion proteins in acute myeloid leukemia.
Martens JH; Stunnenberg HG
FEBS Lett; 2010 Jun; 584(12):2662-9. PubMed ID: 20388510
[TBL] [Abstract][Full Text] [Related]
38. TAF1 plays a critical role in AML1-ETO driven leukemogenesis.
Xu Y; Man N; Karl D; Martinez C; Liu F; Sun J; Martinez CJ; Martin GM; Beckedorff F; Lai F; Yue J; Roisman A; Greenblatt S; Duffort S; Wang L; Sun X; Figueroa M; Shiekhattar R; Nimer S
Nat Commun; 2019 Oct; 10(1):4925. PubMed ID: 31664040
[TBL] [Abstract][Full Text] [Related]
39. AML1-ETO promotes SIRT1 expression to enhance leukemogenesis of t(8;21) acute myeloid leukemia.
Zhou L; Wang Q; Chen X; Fu L; Zhang X; Wang L; Deng A; Li D; Liu J; Lv N; Wang L; Li Y; Liu D; Yu L; Dou L
Exp Hematol; 2017 Feb; 46():62-69. PubMed ID: 27725192
[TBL] [Abstract][Full Text] [Related]
40. FACSorting help to analyze a rare case of acute myeloid leukemia with concurrent AML1-ETO and PML-RARA.
Chen M; Fu M; Wang A; Wu X; Zhen J; Gong M; Wu P; Du Q; Wang T; Liu H; Wang H
Int J Lab Hematol; 2021 Dec; 43(6):e276-e279. PubMed ID: 33943002
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
